Alphamab Oncology to Present Clinical Data of KN026 Combined with KN046 in HER2-positive Solid Tumors at AACR 2022
Alphamab Oncology (stock code: 9966.HK) announced that data from phase II clinical study (KN026-203) of KN026 (HER2 bispecific antibody) combined with KN046 (PD-L1/CTLA-4 bispecific antibody) will be presented by E- poster at the 113th American Association for Cancer Research (AACR 2022) held from April 8-13, 2022.
Founded in 1907, the American Association for Cancer Research (AACR) is one of the largest cancer meetings in the world and widely considered by the global cancer community to be the bellwether that sets the cancer research agenda. It attracts nearly 20,000 professionals from all over the world each year with its spectrum of cancer science and excellent reputation, accelerates the dissemination of new research findings among scientists and others dedicated to the conquest of cancer; promotes science education and training; and advances the public understanding of cancer.
Title: Preliminary Safety and Efficacy Results of KN046 in combination with KN026 in Patients with Locally Advanced Unresectable or Metastatic HER2-positive Solid Cancer
First author: Professor Jifang Gong, Department of Gastrointestinal Oncology, Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education), Peking University Cancer Hospital & Institute, Beijing, China
Poster launch time: April 8, 2022, 1:00 p.m.ET, U.S. time
HER2 gene amplification or overexpression is common in breast cancer and gastric cancer but has also been seen in other solid tumors, including colorectal cancer, non-small cell lung cancer, gallbladder cancer, renal pelvis cancer, pancreatic cancer, etc. Anti-HER2-targeted therapy combined with chemotherapy improves survival outcomes in metastatic HER2-positive malignancies, while the reports of immunotherapy combined with HER2-targeted therapy are still very limited.
KN026-203 is an open-label, phase II, multi-center clinical study to evaluate the efficacy and safety of KN026 combined with KN046 in the treatment of HER2-positive solid tumors, the primary endpoint is the objective response rate (ORR) assessed by the investigator according to RECIST 1.1.
Source: Alphamab Oncology